KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $131.6 million.

  • Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) fell 7.95% to $131.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.6 million, marking a year-over-year decrease of 7.95%. This contributed to the annual value of $143.2 million for FY2024, which is 0.30% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $131.6 million, which was down 2.57% from $135.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $144.6 million for Q1 2024, and its period low was $127.5 million during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $141.0 million, with its median value being $143.0 million (2024).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first increased by 14.00% in 2021, then dropped by 7.95% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $141.7 million in 2021, then increased by 0.32% to $142.1 million in 2022, then climbed by 1.05% to $143.6 million in 2023, then decreased by 0.30% to $143.2 million in 2024, then dropped by 7.95% to $131.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $131.6 million for Q3 2025, versus $135.1 million for Q2 2025 and $137.3 million for Q1 2025.